Boston Scientific Files 8-K on Financial Condition, Operations

TL;DR

**Boston Scientific just updated its financial status, giving investors a fresh look at its books.**

AI Summary

Boston Scientific Corporation filed an 8-K on January 31, 2024, to report on its financial condition and results of operations. This filing indicates that the company is providing an update on its financial standing, including details about its common stock and senior notes due in 2027. For investors, this matters because it offers a snapshot of the company's financial health, which can influence stock performance and future investment decisions.

Why It Matters

This filing provides a current snapshot of Boston Scientific's financial health, which is crucial for investors to assess the company's performance and make informed decisions about their holdings.

Risk Assessment

Risk Level: low — This 8-K filing is a routine disclosure of financial information and does not indicate any immediate or significant new risks.

Analyst Insight

Investors should review the full financial statements and exhibits once they are available to gain a comprehensive understanding of Boston Scientific's current financial health and operational performance.

Key Numbers

• 2024-01-31 — Date of Report (The date of the earliest event reported in the filing.)
• 1-11083 — Commission File Number (Boston Scientific Corporation's SEC file number.)
• 04-2695240 — I.R.S. Employer Identification No. (Boston Scientific Corporation's IRS Employer Identification Number.)

Key Players & Entities

• BOSTON SCIENTIFIC CORPORATION (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for Boston Scientific Corporation
• January 31, 2024 (date) — date of earliest event reported and filing date
• 300 Boston Scientific Way (company) — address of principal executive offices
• Marlborough, Massachusetts (company) — city and state of principal executive offices
• 01752-1234 (company) — zip code of principal executive offices
• 508 683-4000 (company) — registrant's telephone number

Forward-Looking Statements

• Boston Scientific will likely provide more detailed financial results in an upcoming earnings report. (BOSTON SCIENTIFIC CORPORATION) — high confidence, target: Q1 2024 earnings call

FAQ

From the Filing

0000885725-24-000011.txt : 20240131 0000885725-24-000011.hdr.sgml : 20240131 20240131063220 ACCESSION NUMBER: 0000885725-24-000011 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240131 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 24580564 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20240131.htm 8-K bsx-20240131 0000885725 false 0000885725 2024-01-31 2024-01-31 0000885725 us-gaap:CommonStockMember 2024-01-31 2024-01-31 0000885725 bsx:SeniorNotedue2027Member 2024-01-31 2024-01-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   _____________________________________________________________________ Date of Report (Date of earliest event reported): January 31, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                      01752-1234         (Address of Principal Executive Offices)                          (Zip Code) 508 683-4000 (Registrant's telephone number, including area code)  Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ ITEM 2.02.    RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results